'Drug Companies Spurned by Supreme Court on Price Negotiation Law' - Bloomberg News

AstraZeneca PLC
Bristol-Myers Squibb Company
Johnson & Johnson
Novo Nordisk A/S Sponsored ADR Class B
Novartis AG Sponsored ADR

AstraZeneca PLC

AZN

0.00

Bristol-Myers Squibb Company

BMY

0.00

Johnson & Johnson

JNJ

0.00

Novo Nordisk A/S Sponsored ADR Class B

NVO

0.00

Novartis AG Sponsored ADR

NVS

0.00

The US Supreme Court turned away appeals from six pharmaceutical companies seeking to topple the Medicare drug price negotiation program that's led to billions of dollars in discounts on top-selling treatments.

Making no comment, the justices on Monday refused to hear a variety of constitutional arguments against a program created in 2022 by President Joe Biden's Inflation Reduction Act. The court rejected separate appeals from units of AstraZeneca Plc, Johnson & Johnson, Bristol Myers Squibb Co., Novartis AG, Novo Nordisk A/S and Boehringer Ingelheim Pharmaceuticals Inc.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.